52 research outputs found
Bosentan and Fosamprenavir: an effective and safe combination in an HIV-infected patient with pulmonary arterial hypertension
Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in Caucasian patients infected with hepatitis C virus
Introduction. Recent studies have demonstrated the role of the interleukin 28B (IL28B) polymorphisms in predicting treatment induced and spontaneous clearance from Hepatitis C virus (HCV) infection, suggesting the possibility of tailored therapy in HCV infected patients. Genome-wide association studies have shown that single nucleotide polymorphisms (SNPs) near IL 28B gene on chromosome 19 are strong predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin. This study was aimed at analyzing the co-prevalence of two common and clinically significant SNPs in a cohort of Ligurian patients. Methods. Two SNPs (rs12979860, rs8099917) were genotyped in the IL28B locus from 175 DNA samples collected from HCV- infected consecutive patients in a Laboratory of Liguria Region, northern Italy. A real-time polymerase chain reaction in a Cor- bett Research Termocycler (Rotor Gene 3000A) by fluorescent probes (Fast Set IL 28BĂ©, Arrow Diagnostics) was used for the detection, according to the manufacturer?s instructions.
Results. Carriers of rs12979860CT genotype predominated (87/175, 50%), homozygotes for allele C were 68/175 (39%) and the remaining were homozygotes for IFN-resistant allele T (11%). As for the rs8099917 SNP, genotypes were thus distributed: 96/175 (55%) carried the rs8099917 TT genotype, whereas 70/175 (40%) and 9/175 (5%), were heterozygotes or homozygotes for the G allele. The variants rs12979860CC and rs8099917TT were found in 39% and 54% of overall patients with HCV genotype 1, respec- tively. The combined assessment of examined SNPs resulted in three most prevalent genotypes (rs12979860CC/rs8099917TT, rs12979860CT/rs8099917TG and rs12979860CT/rs8099917TT) with a frequency of 35%, 31% and 18%, respectively. Discussion. Recent findings demonstrated that in carriers of rs12979860CT the determination of additional genotype of rs8099917 SNP could significantly improve the prediction of SVR. In our study cohort carriers of rs12979860CT represented 50% of all patients, who could take advantage with respect to SVR prediction by further determination of the rs8099917 SNP. The simultaneous genotyping of two IL28B SNPs should thus be recommended in HCV infected patients prior to treatment initiation
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
Abstract
Introduction
The aim of this study was to analyze the likelihood and the predictors of discontinuation of firstâline regimen in the late HAART era.
Methodology
An observational multiâcenter analysis of HIVâpositive patients enrolled in ICONA. Patients eligible were those starting a firstâline HAART after 1 January 2008. Discontinuation was defined as stop and/or switch of at least one drug of the regimen. All causes of discontinuation, as reported by the treating physician, were evaluated and cumulative risk of stopping was investigated according to age, gender, coâmorbidity, years since starting HAART, immunoâvirological status, third drug and backbone of the first regimen. Kaplan Meier (KM) analysis and Cox proportional hazards model were used for the outcome discontinuation of â„1 drug regardless of the reason. For the KM estimates a competing risk approach was used to estimate the contribution of each of the reasons over time to the cumulative risk of stopping over time.
Results
Data of 1759 patients who started first HAART and had at least one month of clinical followâup were analyzed. The overall discontinuation risk was 33% over a median followâup of 12 months. The likelihood of discontinuation by KM was 27% by one year (95% CI 25â29) and 41% by two years (95% CI 38â44). Main reason for stopping at least one drug in regimen was simplification (10%), followed by intolerance (7%), toxicity (5%), failure (2%) and other causes (8%). Estimates of the cumulative risk of discontinuation of â„1 drug over time and according to reason are shown in Figure 1. In a multivariable Cox model independent predictors of discontinuation regardless of the reason were: longer time from HIV diagnosis to date of starting HAART (hazard ratio [HR] 0.96; 95% CI 0.93â1.00; p=0.039), regimens containing ZDV/3TC (HR 2.86; 95% CI 1.42â5.76; p=0.003 vs TDF/FTC) and an NNRTIâbased regimen (HR 2.47; 95% CI 0.91â6.72; p=0.07 vs regimens not NNRTIâbased).
Conclusions
In a previously reported analysis of the ICONA data [1], the overall risk of discontinuation of firstâline HAART was 36% with 21% due to intolerance/toxicity. In this updated analysis, the main reason for stopping is simplification (accounting for 32% of stops), reflecting the recent changes in recommendations aimed to minimize drug toxicity, enhancing adherence and quality of life
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
Roberta Prinapori,1 Antonio Di Biagio2 1Infectious Diseases, University of Genoa, Genoa, Italy; 2Unit of Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy Abstract: The fixed-dose combination (FDC) elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/c/FTC/TDF) is a once-daily, single-tablet regimen containing an integrase strand transfer inhibitor and a pharmacoenhancer (cobicistat) associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved as the preferred regimen and as the first-line combined antiretroviral therapy in treatment-naïve patients with HIV infection. Two large trials, 102-Study and 103-Study, demonstrated that EVG/c/FTC/TDF was not inferior to efavirenz/FTC/TDF and ritonavir-boosted atazanavir in association with FTC/TDF, in terms of virological suppression and immunological reconstitution through week 144. Also, simplification arms containing EVG/c/FTC/TDF reached noninferiority in comparison with a nonnucleoside reverse transcriptase inhibitor, or a protease inhibitor, or a raltegravir-based regimen. Furthermore, EVG/c/FTC/TDF exhibited an excellent tolerability profile, with a safer lipid profile, and despite the indication of its use in subjects with an estimated creatinine clearance >70 mL/min, recent data demonstrated that EVG/c/FTC/TDF determined a reduction in estimated glomerular filtration rate (GFR) but not a reduction of actual GFR. Moreover, in a cohort of naïve patients with pretreatment mild-to-moderate renal impairment, GFR decrease was noted as early at week 2, after which it generally stabilized and was nonprogressive through week 48. The FDC’s efficacy and good tolerability enable EVG/c/FTC/TDF to meet the patients’ needs, improving adherence and quality of life, which are among the most important factors affecting the therapeutic efficacy of an antiretroviral regimen. This paper describes the evidence making EVG/c/FTC/TDF a new therapeutic opportunity for different HIV-infected patients. Keywords: HIV, once daily, elvitegravir, single-tablet regimen, fixed-dose combination, adherenc
The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults. The pharmacokinetic/pharmacodynamic (PK/PD) linear kinetic profile and long terminal half-life (similar to 393 h) of ORI make it therapeutically attractive for the treatment of other Gram-positive infections for which prolonged therapy is needed. Multidose regimens are adopted in real-world clinical practice with promising results, but aggregated efficacy data are still lacking. A comprehensive search on PubMed/Medline, Scopus, Cochrane and Google Scholar databases was performed to include papers published up to the end of January 2023. All articles on ORI multiple doses usage, including case reports, with quantitative data and relevant clinical information were included. Two reviewers independently assessed papers against the inclusion/exclusion criteria and for methodological quality. Differences in opinion were adjudicated by a third party. From 1751 potentially relevant papers identified by this search, a total of 16 studies met the inclusion criteria and were processed further in the final data analysis. We extracted data concerning clinical response, bacteriologic response, mortality and adverse events (AEs). From the 16 included papers, 301 cases of treatment with multidose ORIs were identified. Multidose regimens comprised an initial ORI dose of 1200 mg followed by 1200 mg or 800 mg subsequent doses with a varying total number and frequency of reinfusions. The most often treated infections and isolates were osteomyelitis (148; 54.4%), ABSSSI (35; 12.9%) and cellulitis (14; 5.1%); and MRSA (121), MSSA (66), CoNS (17), E. faecalis (13) and E. faecium (12), respectively. Clinical cure and improvement by multidose ORI regimens were observed in 85% (231/272) and 8% (22/272) patients, respectively. Multidose ORI was safe and well tolerated; the most frequent AEs were infusion-related reactions and hypoglycemia. A multidose ORI regimen may be beneficial in treating other Gram-positive infections besides ABSSSIs, with a good safety profile. Further studies are warranted to ascertain the superiority of one multidose ORI scheme or posology over the other
Disseminated histoplasmosis with mucocutaneous immune reconstitution inflammatory syndrome in an HIV-infected patient
Predictors of retention in care for HIV-infected patients: data from San Martino Hospital cohort in Genoa
Background: Retention in care (RC) is a key feature of the cascade of continuum of care that moves from HIV testing to linkage to care, engagement in care and RC. RC play an important role in achieving and maintaining therapeutic success and is crucial for reduction of HIV transmission. The aim of this study was to evaluate the rate of RC in the Infectious Disease unit of San Martino Hospital, in Genoa and to identify predictors associated with failed RC.
Methods: All new HIV tested and diagnosed subjects were consecutively enrolled from 01/01/2008 to 01/08/2014. Follow-up period was censored at 01 February 2015. Demographics, immune-virological status, co-infection with HCV and HBV and therapeutic data were collected at baseline and at the time of last observation. Failed RC was defined as lack of laboratory data, clinical visits and drug dispensation for more than 6 months. Causes of failed RC were recorded, if available.
Total and partial frequencies were calculated for categorical variables, while media and median were computed for continuous variables .The relationship between the RC and the parameters taken into account was examined with a univariate analysis, using Chi-squared test for dichotomous outcome variables and the Student\u2019s T test for the continuous outcome variables to evaluate the P values. The level of significance was set at P <0.05.
Results: we enrolled 209 patients (mean age 45.1 years). Males were 152 (73%), Italian 169 (81%) with mean length of disease of 43.8 months. Co-infection HBV/HIV and HCV/HIV were present in 7 (3%) and 30 (14%) patients respectively. At baseline mean lymphocyte T cell CD4+ was 267/mmc with 46% of subjects with CD4+ <200/mmc of which 42% <50/mmc. HIV-RNA was over 100,000 copies for 38% of patients. Antiretroviral therapy (cART) was prescribed for 194 patients (93%). The rate of RC was 82%. Among patients who failed retaining in care 9 (24%) died and 6 (16%) moved to other medical centers. Differences between patients retained in care and lost at follow up are showed in table 1. Failed RC was associated with foreign origin (p=0.016), HBV/HIV co-infection (p=0.005), CD4+ count <200/mmc and HIV-RNA greater than 50 copies/ml at observation time (p<0.0001 respectively) and being not treated for HIV-infection (p<0.0001).
Conclusions: The rate of RC in San Martino cohort is similar than compared to those estimated for US and Italian cohorts (81% and 85%). Foreign origin and lack of prescription of initial cART are the key factors in RC
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in na\uefve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future
Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
Risk associated with a systematic search of extended-spectrum \u3b2-lactamase-producing Enterobacteriaceae.
- âŠ